Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.68 |
| ▸ | CDK9 | P50750 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945487 | 0.99 | CCNT1 (0.67) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1947792 | 0.96 | CCNT1 (0.70) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1948052 | 0.94 | CCNT1 (0.63) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1945131 | 0.93 | CCNT1 (0.70) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1946122 | 0.93 | CCNT1 (0.73) | CCNT1CDK9 | |
| SCHEMBL1949097 | 0.92 | CCNT1 (0.69) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1947977 | 0.92 | CCNT1 (0.59) | CCNT1CDK9HDAC3HDAC1HDAC6 | |
| SCHEMBL1949075 | 0.92 | CCNT1 (0.77) | CCNT1CDK9 | |
| SCHEMBL1947987 | 0.92 | CCNT1 (0.77) | CCNT1CDK9 | |
| SCHEMBL1462005 | 0.92 | CCNT1 (0.77) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CCNT1 47/4885CDK9 5/4885HDAC3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.